mAb-话题@MedSci

#mAb#

1302篇内容 | 2837人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912883, encodeId=e80d191288311, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, objectType=article, longId=734229, objectId=6890e34229fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6890e34229fe, replyNumber=0, likeNumber=86, createdTime=2022-10-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6890e34229fe, moduleTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6890e34229fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912842, encodeId=00f8191284282, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), objectType=article, longId=724472, objectId=bbc0e244722a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc0e244722a, replyNumber=0, likeNumber=65, createdTime=2022-12-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc0e244722a, moduleTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc0e244722a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912885, encodeId=f1dd1912885b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：cinpanemab治疗早期帕金森病失败, objectType=article, longId=734862, objectId=5e7de34862d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e7de34862d3, replyNumber=0, likeNumber=94, createdTime=2023-05-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e7de34862d3, moduleTitle=NEJM：cinpanemab治疗早期帕金森病失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e7de34862d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912876, encodeId=14f619128e664, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:Dupilumab治疗时出现面部皮炎需要特殊处理吗？, objectType=article, longId=731285, objectId=a5aae31285cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5aae31285cb, replyNumber=0, likeNumber=74, createdTime=2022-07-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5aae31285cb, moduleTitle=JEADV:Dupilumab治疗时出现面部皮炎需要特殊处理吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5aae31285cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912899, encodeId=cc7b1912899d9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, objectType=article, longId=739152, objectId=0ec4e39152ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec4e39152ac, replyNumber=0, likeNumber=102, createdTime=2023-08-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec4e39152ac, moduleTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec4e39152ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912807, encodeId=2c16191280ec3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Br J Dermatol：Risankizumab治疗中到重度银屑病的安全性研究, objectType=article, longId=299904, objectId=c61729990464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c61729990464, replyNumber=0, likeNumber=87, createdTime=2022-07-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c61729990464, moduleTitle=Br J Dermatol：Risankizumab治疗中到重度银屑病的安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c61729990464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912803, encodeId=3ff41912803f9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV：Dupilumab特应性皮炎患者的眼部副作用, objectType=article, longId=299547, objectId=df8a29954e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df8a29954e83, replyNumber=0, likeNumber=72, createdTime=2022-07-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df8a29954e83, moduleTitle=JEADV：Dupilumab特应性皮炎患者的眼部副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df8a29954e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912843, encodeId=b96419128432f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA解除Magrolimab治疗MDS和AML的临床研究的限制, objectType=article, longId=724488, objectId=eb97e24488ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb97e24488ca, replyNumber=0, likeNumber=102, createdTime=2022-08-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb97e24488ca, moduleTitle=FDA解除Magrolimab治疗MDS和AML的临床研究的限制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb97e24488ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912873, encodeId=4cfc19128e391, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, objectType=article, longId=729628, objectId=bf1ee296289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1ee296289d, replyNumber=0, likeNumber=103, createdTime=2022-12-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1ee296289d, moduleTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1ee296289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912861, encodeId=83e41912861ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, objectType=article, longId=728406, objectId=362fe28406f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362fe28406f5, replyNumber=0, likeNumber=95, createdTime=2022-09-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362fe28406f5, moduleTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=362fe28406f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912888, encodeId=540119128887a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=735741, objectId=dd07e3574140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd07e3574140, replyNumber=0, likeNumber=104, createdTime=2023-06-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd07e3574140, moduleTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd07e3574140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912838, encodeId=3d23191283826, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, objectType=article, longId=723522, objectId=d134e23522a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d134e23522a2, replyNumber=0, likeNumber=77, createdTime=2023-02-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d134e23522a2, moduleTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d134e23522a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912792, encodeId=cef21912e92cf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, objectType=article, longId=295542, objectId=e92329554273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92329554273, replyNumber=0, likeNumber=97, createdTime=2022-10-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92329554273, moduleTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92329554273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912869, encodeId=6812191286951, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险, objectType=article, longId=729950, objectId=a49de299506f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a49de299506f, replyNumber=0, likeNumber=0, createdTime=2023-04-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a49de299506f, moduleTitle=JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a49de299506f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912811, encodeId=2caf1912811b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=呼吸道合胞病毒（RSV）抗体Nirsevimab，试验取得积极结果, objectType=article, longId=300120, objectId=79c9300120d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c9300120d3, replyNumber=0, likeNumber=91, createdTime=2022-08-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c9300120d3, moduleTitle=呼吸道合胞病毒（RSV）抗体Nirsevimab，试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c9300120d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912785, encodeId=56bf1912e8574, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, objectType=article, longId=295347, objectId=691929534ef4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=691929534ef4, replyNumber=0, likeNumber=60, createdTime=2022-11-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=691929534ef4, moduleTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=691929534ef4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912778, encodeId=5ebf1912e7810, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, objectType=article, longId=294727, objectId=65f8294e27ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65f8294e27ca, replyNumber=0, likeNumber=100, createdTime=2022-09-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65f8294e27ca, moduleTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65f8294e27ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912864, encodeId=d915191286429, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JACIP:Dupilumab单抗治疗能够减少成人中重度特应性皮炎的住院率, objectType=article, longId=728035, objectId=42dee280353e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42dee280353e, replyNumber=0, likeNumber=83, createdTime=2022-10-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42dee280353e, moduleTitle=JACIP:Dupilumab单抗治疗能够减少成人中重度特应性皮炎的住院率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42dee280353e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912762, encodeId=5eea1912e6215, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), objectType=article, longId=293431, objectId=ec882934312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec882934312f, replyNumber=0, likeNumber=75, createdTime=2022-08-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec882934312f, moduleTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec882934312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912856, encodeId=04d51912856db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=92, createdTime=2022-09-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤

2022-10-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC)

2022-12-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：cinpanemab治疗早期帕金森病失败

2023-05-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:Dupilumab治疗时出现面部皮炎需要特殊处理吗？

2022-07-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗

2023-08-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Br J Dermatol：Risankizumab治疗中到重度银屑病的安全性研究

2022-07-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV：Dupilumab特应性皮炎患者的眼部副作用

2022-07-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA解除Magrolimab治疗MDS和AML的临床研究的限制

2022-08-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效

2022-12-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究

2022-09-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤

2023-06-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性

2023-02-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤

2022-10-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险

2023-04-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

呼吸道合胞病毒（RSV）抗体Nirsevimab，试验取得积极结果

2022-08-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果

2022-11-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗

2022-09-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JACIP:Dupilumab单抗治疗能够减少成人中重度特应性皮炎的住院率

2022-10-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16)

2022-08-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-09-08

科室
- - 订阅+
  - 更多科室
工具
服务